Apr 24, 2019

Early results positive for nivolumab as first-line therapy in advanced NSCLC | MDedge Hematology and Oncology

Key clinical point: A phase I trial indicates that nivolumab is safe and shows durable activity as a first-line therapy in treating patients with advanced NSCLC. Major finding: Grade 3 or 4 adverse events were reported in 19% of patients.

Proceed to the page: http://linkis.com/Akn7d

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent mdedge.com Articles

Latest Links Processed